Xbrane Reveals Urgency To Find A Partner For One Of Two Biosimilars By October
Initial Discussions Held On Biosimilar Cimzia After Biogen Exited Project
Cash is king for fledgling biosimilar companies. Xbrane Biopharma has revealed just how close it is to the edge after Biogen unexpectedly pulled the plug on a key licensing deal, but the company is maintaining optimism.
